http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 Oct 2026 19:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16++Filed+by%3A+Bono+Raquel+C./27211519.html si-local-file:///var/storage/secattach/20261020/27211519.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16++Filed+by%3A+Bono+Raquel+C./27211519.html Tue, 20 Oct 2026 19:05:00 -0400 VXRT http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16++Filed+by%3A+Bono+Raquel+C./27211518.html si-local-file:///var/storage/secattach/20261020/27211518.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16++Filed+by%3A+Bono+Raquel+C./27211518.html Tue, 20 Oct 2026 19:04:00 -0400 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16/27203908.html si-local-file:///var/storage/secattach/20261019/27203908.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Oct+16/27203908.html Mon, 19 Oct 2026 16:07:00 -0400 VXRT http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html <p>Vaxart, Inc. (OTCQB: VXRT) has appointed Raquel "Rocky" C. Bono, M.D., a retired U.S. Navy Vice Admiral, to its board of directors, according to a company statement.</p> <p>Dr. Bono's appointment follows a cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She will serve as Chair of the Stockholder Engagement Committee and as a member of the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.</p> <p>Dr. Bono is a board-certified trauma surgeon who previously served as Director of the Defense Health Agency, where she oversaw a $50 billion integrated global healthcare system serving 9.5 http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html Mon, 19 Oct 2026 08:01:08 -0400 HUM VIK VXRT http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html <p>Vaxart, Inc. (OTCQB: VXRT) has appointed Raquel "Rocky" C. Bono, M.D., a retired U.S. Navy Vice Admiral, to its board of directors, according to a company statement.</p> <p>Dr. Bono's appointment follows a cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She will serve as Chair of the Stockholder Engagement Committee and as a member of the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.</p> <p>Dr. Bono is a board-certified trauma surgeon who previously served as Director of the Defense Health Agency, where she oversaw a $50 billion integrated global healthcare system serving 9.5 http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html Mon, 19 Oct 2026 08:01:08 -0400 HUM VIK VXRT http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html <p>Vaxart, Inc. (OTCQB: VXRT) has appointed Raquel "Rocky" C. Bono, M.D., a retired U.S. Navy Vice Admiral, to its board of directors, according to a company statement.</p> <p>Dr. Bono's appointment follows a cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She will serve as Chair of the Stockholder Engagement Committee and as a member of the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.</p> <p>Dr. Bono is a board-certified trauma surgeon who previously served as Director of the Defense Health Agency, where she oversaw a $50 billion integrated global healthcare system serving 9.5 http://www.streetinsider.com/Board+Changes/Vaxart+adds+retired+vice+admiral+and+surgeon+to+its+board/27200974.html Mon, 19 Oct 2026 08:01:08 -0400 HUM VIK VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Press+Releases/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html <p align="center"><em>Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel “Rocky” C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors.</p> <p>Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She http://www.streetinsider.com/Globe+Newswire/Vaxart+Appoints+Retired+Vice+Admiral+Raquel+C.+Bono%2C+M.D.%2C+to+Board+of+Directors/27200933.html Mon, 19 Oct 2026 08:00:00 -0400 HUM VIK VXRT http://www.streetinsider.com/Corporate+News/Vaxart+publishes+H5N1+oral+vaccine+preclinical+data+in+ferrets/27164445.html <p>Vaxart, Inc. (OTCQX: VXRT) announced the publication of preclinical study results for its oral H5N1 vaccine candidate, VXA-H5-02, in the peer-reviewed journal <em>Frontiers in Immunology</em>. The study, conducted in ferrets, showed 100% survival following exposure to a lethal dose of H5N1 clade 2.3.4.4b virus.</p><p>All unvaccinated control animals died by day six post-challenge, while all ferrets immunized with VXA-H5-02 survived. The vaccine also produced approximately a 2.3-log reduction in infectious viral shedding by day three post-challenge compared to controls. By days six to seven, viable virus fell below the limit of detection in nasal wash samples, and seven of eight animals http://www.streetinsider.com/Corporate+News/Vaxart+publishes+H5N1+oral+vaccine+preclinical+data+in+ferrets/27164445.html Thu, 08 Oct 2026 08:41:19 -0400 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Publication+of+Preclinical+Study+Demonstrating+100%25+Protection+Against+a+Lethal+Dose+of+H5N1+Avian+Flu+in+a+Ferret+Challenge+Model/27164442.html <p align="center"><em>Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet, today announced the publication of positive preclinical study results evaluating its adenovirus-based oral mucosal vaccine platform against Highly Pathogenic Avian Influenza (HPAI) H5N1, a pathogenic virus that poses a significant threat to public health. The complete, peer-reviewed study results, which were published in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9FVv-LqWrJt7xmY4i2MsW2LJOJU3Cy77OFkwDw8k8ngRK6ksOokSGJqaO-e7TgYFKH-tIOTr-9wMn3Hk0aJiZB6tTX9U62v7KTVj9ZGwgDdyQ16NUgRUNqGK6WktVcOmhm_HEMlNu--jeQ6S502q9klbIhEAVH_WHrwT3YS2HL8Da4D6doG0OJJUJYkWE2sF" rel="nofollow" target="_blank"><em>Frontiers in http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Publication+of+Preclinical+Study+Demonstrating+100%25+Protection+Against+a+Lethal+Dose+of+H5N1+Avian+Flu+in+a+Ferret+Challenge+Model/27164442.html Thu, 08 Oct 2026 08:40:00 -0400 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Publication+of+Preclinical+Study+Demonstrating+100%25+Protection+Against+a+Lethal+Dose+of+H5N1+Avian+Flu+in+a+Ferret+Challenge+Model/27164442.html <p align="center"><em>Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge</em></p> <p>SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered via tablet, today announced the publication of positive preclinical study results evaluating its adenovirus-based oral mucosal vaccine platform against Highly Pathogenic Avian Influenza (HPAI) H5N1, a pathogenic virus that poses a significant threat to public health. The complete, peer-reviewed study results, which were published in <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9FVv-LqWrJt7xmY4i2MsW2LJOJU3Cy77OFkwDw8k8ngRK6ksOokSGJqaO-e7TgYFKH-tIOTr-9wMn3Hk0aJiZB6tTX9U62v7KTVj9ZGwgDdyQ16NUgRUNqGK6WktVcOmhm_HEMlNu--jeQ6S502q9klbIhEAVH_WHrwT3YS2HL8Da4D6doG0OJJUJYkWE2sF" rel="nofollow" target="_blank"><em>Frontiers in http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Publication+of+Preclinical+Study+Demonstrating+100%25+Protection+Against+a+Lethal+Dose+of+H5N1+Avian+Flu+in+a+Ferret+Challenge+Model/27164442.html Thu, 08 Oct 2026 08:40:00 -0400 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Sep+03/27091839.html si-local-file:///var/storage/secattach/20260922/27091839.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Sep+03/27091839.html Tue, 22 Sep 2026 17:10:00 -0400 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Sep+03/27058416.html si-local-file:///var/storage/secattach/20260914/27058416.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Sep+03/27058416.html Mon, 14 Sep 2026 16:05:00 -0400 VXRT http://www.streetinsider.com/Corporate+News/Vaxart+receives+European+patent+for+oral+norovirus+vaccine+technology/26981657.html <p>Vaxart, Inc. (OTCQX: VXRT) announced that the European Patent Office granted the company European Patent No. 3791859, published Aug. 26, 2026, covering key aspects of its oral recombinant norovirus vaccine candidate.</p><p>The patent provides intellectual property protection through at least 2036 across 13 European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom. Additional countries where the patent will be validated include Austria, Belgium, Denmark, Ireland, Netherlands, Norway, Sweden, and Switzerland.</p><p>The patent covers elements of Vaxart's pill-based vaccine delivery technology, which the company describes as room-temperature stable and needle-free.</p><p>"Securing this patent expands our global intellectual property portfolio and secures additional http://www.streetinsider.com/Corporate+News/Vaxart+receives+European+patent+for+oral+norovirus+vaccine+technology/26981657.html Wed, 26 Aug 2026 16:08:16 -0400 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Globe+Newswire/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html <p>KEY HIGHLIGHTS:<br/>• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart&apos;s oral recombinant norovirus vaccine candidate.<br/>• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.<br/>• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart&apos;s room-temperature stable, needle-free pill technology for the use of against norovirus.</p> <p>SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range http://www.streetinsider.com/Press+Releases/Vaxart+Expands+Intellectual+Property+Portfolio+with+European+Patent+Protecting+Proprietary+Norovirus+Vaccine+Technology/26981630.html Wed, 26 Aug 2026 16:07:00 -0400 A.03718595 O.04906507 O.20329759 VXRT